Both routes deliver bioequivalent doses when properly dosed, meaning your body processes and responds to the medication in substantially the same way
Cagrilintide, survodutide, and orforglipron are all in the pipeline
Millions of women use the low-cal sweetener, sold as Splenda, instead of sugar
adults: an analysis of the National Health and Nutrition Examination Survey
To view or add a comment, sign in On behalf of our affiliate company, Portal Therapeutics, we're excited to announce positive data from the Phase 2a GATEWAY trial of PORT-77 in patients with erythropoietic #protoporphyria (EPP)
They argue that the appropriate response is not a blanket ban but a structured framework: quality-controlled compounding, mandatory prescriber oversight, and data collection that builds the evidence base over time